Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimavanserin Tartrate

FDA-approved product (tablet, oral), marketed as Nuplazid, Pimavanserin.

Registered studies
46
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pimavanserin Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hallucinations
  • Parkinson disease
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimavanserin Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimavanserin Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Psilocybin Efficacy With or Without Pimavanserin Pretreatment

    NCT07610135 · start 2026-09-30

    Registered record
    Registry ID
    NCT07610135
    Conditions
    Mood (Psychological Function); Well Being; Mood; Healthy
    Interventions
    Psilocybin; Pimavanserin; Inactive Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-09-30
    Completion
    2028-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMood (Psychological Function); Well Being; Mood; Healthy
    InterventionPsilocybin; Pimavanserin; Inactive Placebo
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

    NCT05999240 · start 2025-10-01

    Registered record
    Registry ID
    NCT05999240
    Conditions
    Autism Spectrum Disorder
    Interventions
    Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-01
    Completion
    2027-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder
    InterventionPimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

    NCT06592833 · start 2025-02-25

    Registered record
    Registry ID
    NCT06592833
    Conditions
    Major Depressive Disorder
    Interventions
    Psilocybin; Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-02-25
    Completion
    2028-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionPsilocybin; Pimavanserin; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Investigating the Neuropsychological Effects of 5-HT2a Antagonism

    NCT07022366 · start 2025-02-10

    Registered record
    Registry ID
    NCT07022366
    Conditions
    Healthy
    Interventions
    Pimavanserin 10mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-02-10
    Completion
    2026-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPimavanserin 10mg; Placebo
    PhaseNot applicable
    Registry statusRecruiting

  • Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

    NCT06754553 · start 2025-02

    Registered record
    Registry ID
    NCT06754553
    Conditions
    Parkinson Disease
    Interventions
    Assessment of severity of ICD (impulse control disorders); Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Assessment of quality of life; Assessment of depression; Assessment of cognition; Assessment of severity of Parkinson Disease; Cardiac monitoring
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-02
    Completion
    2026-02
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionAssessment of severity of ICD (impulse control disorders); Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Assessment of quality of life; Assessment of depression +3 more
    PhaseNot recorded
    Registry statusNot yet recruiting

  • The Sub-Sero Study

    NCT03994965 · start 2024-12-01

    Registered record
    Registry ID
    NCT03994965
    Conditions
    Schizophrenia; Psychosis
    Interventions
    Pimavanserin 34 milligrams (MG) [Nuplazid]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-12-01
    Completion
    2024-12-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychosis
    InterventionPimavanserin 34 milligrams (MG) [Nuplazid]
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

    NCT06068465 · start 2024-09-27

    Registered record
    Registry ID
    NCT06068465
    Conditions
    Parkinson's Disease Psychosis
    Interventions
    pimavanserin tartrate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-09-27
    Completion
    2026-02-01
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis
    Interventionpimavanserin tartrate; placebo
    PhasePhase 3
    Registry statusCompleted

  • Psilocybin Therapy for Depression in Parkinson's Disease

    NCT06455293 · start 2024-08-19

    Registered record
    Registry ID
    NCT06455293
    Conditions
    Parkinson Disease; Depression
    Interventions
    Psilocybin; Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-19
    Completion
    2028-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Depression
    InterventionPsilocybin; Pimavanserin
    PhasePhase 2
    Registry statusRecruiting

  • Pimavanserin and Aggression and Social Cognition.

    NCT05895513 · start 2024-08-01

    Registered record
    Registry ID
    NCT05895513
    Conditions
    Intermittent Explosive Disorder
    Interventions
    Pimavanserin 34 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-01
    Completion
    2028-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntermittent Explosive Disorder
    InterventionPimavanserin 34 mg; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Bioequivalence Study of Pimavanserin 34 mg Capsule

    NCT06450184 · start 2024-01-11

    Registered record
    Registry ID
    NCT06450184
    Conditions
    Parkinson Disease Psychosis
    Interventions
    Pimavanserin 34 mg; NUPLAZID 34 MG Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-01-11
    Completion
    2024-03-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease Psychosis
    InterventionPimavanserin 34 mg; NUPLAZID 34 MG Oral Capsule
    PhasePhase 1
    Registry statusCompleted

  • Pimavanserin for Insomnia in Veterans With PTSD

    NCT05441280 · start 2023-12-28

    Registered record
    Registry ID
    NCT05441280
    Conditions
    Post-traumatic Stress Disorder; Insomnia
    Interventions
    pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-12-28
    Completion
    2027-07-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-traumatic Stress Disorder; Insomnia
    Interventionpimavanserin; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Pimavanserin for Sleep in Parkinson Disease

    NCT05796167 · start 2023-01-27

    Registered record
    Registry ID
    NCT05796167
    Conditions
    Parkinson Disease
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2023-01-27
    Completion
    2024-06-24
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionPimavanserin
    PhaseEarly phase 1
    Registry statusWithdrawn

  • Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

    NCT05357612 · start 2023-01-23

    Registered record
    Registry ID
    NCT05357612
    Conditions
    Neurodegenerative Diseases; Parkinson Disease; Parkinson Disease Psychosis
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-01-23
    Completion
    2027-08
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurodegenerative Diseases; Parkinson Disease; Parkinson Disease Psychosis
    InterventionPimavanserin
    PhasePhase 4
    Registry statusRecruiting

  • Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

    NCT04809116 · start 2022-12-15

    Registered record
    Registry ID
    NCT04809116
    Conditions
    Insomnia Chronic; Posttraumatic Stress Disorder
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2022-12-15
    Completion
    2023-12-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia Chronic; Posttraumatic Stress Disorder
    InterventionPimavanserin
    PhasePhase 4
    Registry statusWithdrawn

  • Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

    NCT05555615 · start 2022-11-02

    Registered record
    Registry ID
    NCT05555615
    Conditions
    Irritability Associated With Autism Spectrum Disorder
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2022-11-02
    Completion
    2025-02-14
    Enrolment
    209

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritability Associated With Autism Spectrum Disorder
    InterventionPimavanserin
    PhasePhase 2 / Phase 3
    Registry statusTerminated